CDA and pancreatic neoplasm: More recently, it has been demonstrated that nab-paclitaxel in combination with gemcitabine for pancreatic cancer patients increases dFdCTP concentration in tumor tissues and that, as an explanation for this observation, nab-paclitaxel and paclitaxel decrease the protein expression of cytidine deaminase in vivo and in vitro, respectively [34].